Inflammatory phenotypes underlying uncontrolled childhood asthma despite inhaled corticosteroid treatment: rationale and design of the PACMAN2 study

Table 1 Inclusion criteria PACMAN2 study

Long-term uncontrolled	Long-term controlled
• Parental consent to be approached for future research	• Parental consent to be approached for future research
• 8 years of age or older	• 8 years of age or older
• Current ICS user	• Current ICS user
• Adherent to corticosteroids (MARS≥21)‡	• Adherent to corticosteroids (MARS≥21)‡
• Long-term uncontrolled in the past year‡	• Long-term controlled asthma in the past year‡
≥ 3 seasons in the past year in which symptoms were uncontrolled:	≥ 3 seasons in the past year in which symptoms were controlled:
o ≥ 3 of the following symptoms (daily or weekly)	o Following symptoms are not present or occur less than weekly:
▪ Daytime asthma symptoms (cough, wheeze, shortness of breath)	▪ Daytime asthma symptoms (cough, wheeze, shortness of breath)
▪ Nighttime asthma symptoms	▪ Nighttime asthma symptoms
▪ Limitations in daily activities	▪ Limitations in daily activities
▪ Rescue medication use	▪ Rescue medication use
	• No asthma-related ER visit in the past year‡
	• No OCS use in the past year‡

‡ Based on the retrospective questionnaire data obtained during the PACMAN pharmacy study visit (baseline). Current ICS use was confirmed during telephone contact prior to the follow up study visit. ICS Inhaled Corticosteroids, MARS Medication Adherence Report Scale, OCS Oral Corticosteroids, ER Emergency Room.

ISSN: 1471-2431